{
    "2020-10-18": [
        [
            {
                "time": "2021-10-15",
                "original_text": "What Should Investors Know About Eli Lilly's Coronavirus Antibody Treatments?",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Coronavirus",
                        "Antibody Treatments"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10-15",
                "original_text": "Eli Lilly Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Shareholder Notice",
                        "Losses",
                        "Faruqi & Faruqi"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "legal",
                        "investor relations"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-10-15",
                "original_text": "Eli Lilly To Snap Up Disarm In $135M Deal; Street Stays Bullish",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Acquisition",
                        "Disarm",
                        "$135M",
                        "Bullish"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}